Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial - Aix-Marseille Université Access content directly
Journal Articles European Urology Oncology Year : 2021

Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial

Bernadett Szabados
  • Function : Author
Alejo Rodriguez-Vida
  • Function : Author
Ignacio Durán
  • Function : Author
Simon Crabb
  • Function : Author
Michiel van Der Heijden
  • Function : Author
Albert Font Pous
  • Function : Author
Urbano Anido Herranz
  • Function : Author
Andrew Protheroe
  • Function : Author
Alain Ravaud
Denis Maillet
  • Function : Author
  • PersonId : 761687
  • IdRef : 262879662
Maria Mendez-Vidal
  • Function : Author
Cristina Suárez
  • Function : Author
Mark Linch
  • Function : Author
Aaron Prendergast
  • Function : Author
Charlotte Tyson
  • Function : Author
Kelly Mousa
  • Function : Author
Daniel Castellano
  • Function : Author
Thomas Powles
  • Function : Author

Domains

Cancer
No file

Dates and versions

hal-03623603 , version 1 (29-03-2022)

Identifiers

Cite

Bernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, Simon Crabb, Michiel van Der Heijden, et al.. Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. European Urology Oncology, 2021, 4 (3), pp.456-463. ⟨10.1016/j.euo.2020.11.010⟩. ⟨hal-03623603⟩

Collections

CNRS UNIV-AMU CRCM
6 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More